CIMAvax-EGF, a protein-specific vaccine intended to inhibit the EGFR, a protein excessively expressed on NSCLC cells, has exhibited both safety and efficacy in several clinical trials conducted within Cuba (273). Here, EGFR is linked to non-small cell lung carcinoma.